Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.
To compare risk of hospitalization in patients with bipolar I disorder (BD-I) initiating long-acting injectable antipsychotics (LAIs). Using Truven Health Analytics MarketScan® (Medicaid, Commercial and Medicare Supplemental) databases (2012-2016), patients (≥18 years) with BD-I with a LAI (aripiprazole once monthly [AOM 400], fluphenazine-LAI, haloperidol-LAI, risperidone-LAI and paliperidone-4-week-LAI) were identified. The adjusted odds of having hospitalization were significantly higher in haloperidol-LAI (Odds ratio [95% CI]: 1.39 [1.03-1.87] all-cause; p = 0.029; 1.41 [1.03-1.93] psychiatric-specific; p = 0.032) and risperidone-LAI (1.54 [1.12-2.13]; p = 0.009; 1.68 [1.20-2.37]; p = 0.003) users versus AOM 400 users. Risks of hospitalization did not differ comparing fluphenazine-LAI and paliperidone-LAI users with AOM 400 users. AOM 400 may be more beneficial at reducing hospitalization rates in BD-I versus haloperidol-LAI and risperidone-LAI.